May 19, 2020

Gail Kelly Retiring From Westpac, Offers Advice For Future Leaders

Banking
CEO
finance
Westpac
We Photo Booth You
2 min
Gail Kelly Retiring From Westpac, Offers Advice For Future Leaders

Gail Kelly is retired from Westpac Banking Corp.

The CEO of seven years will step down in February of 2015; the top spot will be filled by Brian Hartzer. Hartzer has been the chief executive of Westpac’s Australian Financial Services business since 2012.

“The CEO transition will be seamless and Hartzer’s appointment is no surprise,” said Don Williams, Sydney-based founder and chief investment officer at Platypus Asset Management. “The challenge for Hartzer is the same as the challenge for all Australian banks—declining earnings momentum and the prospect of carrying more capital due to regulatory changes.”

“Gail leaves the Group in strong shape, and well placed to compete in the next phase of our strategy.” Said Chairman Lindsay Maxsted.

Kelly became the first female CEO of a major Australian bank and has been very successful in her tenure: the profits of the bank have more than doubled under her leadership.

At her press conference announcing her retirement, Kelly was able to offer the audience a few gems of advice.

* “Back yourself, ask for opportunities and dig deep when those opportunities come your way and have a go.”

* “You should actively choose to be positive, to see the world through a glass-half-full perspective. You should choose, even in difficult times, to look for the learning, the insights, the opportunities, the next steps.”

* “If you love what you do, you’ll do more of it; doing more of it, you’ll gather more confidence, more energy and get better at it. That builds more confidence and energy and you love it more.”

* “If you believe in practicing generosity of spirit, at heart you believe in the power of an individual to make a difference and at heart you treat individuals with deep respect and want to see others flourish.”

Information sourced from Bloomberg.

Share article

Jun 13, 2021

Seo JungJin: Who is EY’s World Entrepreneur of 2021?

EY
entrepreneurs
Leadership
celltrion
Kate Birch
3 min
From just US$45,000 capital in 2003 to a world-leading biopharma giant with revenues of US$1.69bn today, Seo JungJin is crowned EY World Entrepreneur 2021

Seo JungJin, founder of biopharma firm Celltrion, which most recently developed an antibody treatment for COVID-19, has been named the EY World Entrepreneur of the Year 2021, becoming the first South Korean in the award’s 21-year history.

Regarded as one of the world’s most prestigious business awards program for entrepreneurs, the EY Entrepreneur of the Year celebrates visionary and innovative leaders from across 60 countries who are transforming the world and fostering growth.

JungJin, who is now honoroary chairman of Celltrion Group, was up against a worthy cast of entrepreneurial competitors, taking the crown from among 45 award winners across 38 countries and territories.

Speaking during the virtual event, JungJin described his own interpretation of entrepreneurship as something that brings together “a group of people toward a common vision, embracing challenges as opportunities and committing oneself to contribute to the greater good”.

Why was JungJin crowned King Entrepreneur?

A South Korean native and now 63 years of age, JungJin founded biopharmaceutical firm Celltrion in 2003. In the nearly two decades since its founding, Celltrion has lived up to its goal of advancing health and welfare for all by developing ground-breaking drugs to treat autoimmune disease, various forms of cancer and, most recently, COVID-19.

The company, which JungJin started with just US$45,000 and five of his colleagues, has since growth to more than 2,1000 employees with sales permits in more than 90 countries and revenues exceeding US$1.69bn.

According to the panel, JungJin’s story is a shining example of the power of an unstoppable entrepreneur to change the world with the pandel moved by both his incredible story and his purpose-driven leadership, innovative mindset and entrepreneurial spirit.

Described by the chair of the EY judging panel Rosaleen Blair as “representing everything an unstoppable should be” from taking on the world’s biggest health care challenges to consistently creating long-term value for his company, JungJin’s story is one of incredible tenacity and perseverance that the judging panel felt most represented the entrepreneurial spirit.

“He’s taken breathtaking risks, both personal and professional, to found Celltrion and grow it into one of the world’s leading biopharmaceutical companies,” says Stasia Mitchell, EY Global Entrepreneurship Leader. “His passion for creating affordable, life-saving health care and flair for tackling global problems has led to many treatments that have helped millions of people worldwide and was especially evident this past year through the creation of a COVID-19 antibody treatment.”

How did JungJin get there?

JungJin's entrepreneurial journey started at an early age when he worked as a taxi driver to get himself through Konkuk University in Seoul, South Korea. After studying industrial engineering, he rose through the ranks of Daewoo Motor Co. before losing his job amid the carmaker’s financial troubles following the 1997 Asian economic crisis.

Following this, JungJin started collaborating with colleagues to explore business opportunities in different industries, though none delivered lasting success. The turning point came after he attended a talk hosted by renowned scholars, which inspired him to focus on the biopharmaceutical sector.

And so he founded Celltrion with just US$45,000 of his savings. The launch of Remsima, credited with being the world's first antibody biosimilar, quickly moved Celltrion up the ranks of the country's fairly underdeveloped pharmaceutical sector. Celltrion followed this success with the launch of drugs for breast cancer and lymphoma that today are being used worldwide.

With ambitions to be the world’s first in different areas, Celltrion has pioneered numerous uncharted areas to great success over the past two decades, most recently responding to the global pandemic by successfully developing an antibody treatment for COVID-19 and working to ensure a timely supply of the safe and effective treatment.

“When I first started, my vision was to help patients gain access to safe, effective and affordable medicines and thereby enhance the quality of people’s lives,” explains JungJin. “The success of Celltrion has enabled me to expand on this while finding new ways to fuel my entrepreneurial drive.”

 

Share article